Meniere's Disease (Vestibular Attack Frequency)
Investigational adjunct for vestibular attack frequency reduction in definite Meniere's disease per AAO-HNS 2015 criteria; case-series evidence.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for Meniere disease vestibular attacks. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Какие доказательства существуют?
- Tier C (investigational). Case reports only; no controlled trials in Meniere disease. Evidence-based first-line management is dietary sodium restriction, diuretic therapy (usually thiazide), vestibular rehabilitation, and for refractory cases intratympanic steroid or gentamicin and ultimately endolymphatic sac surgery or labyrinthectomy.
- Основные риски
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Worsening dizziness, nausea, or imbalance immediately after a session
- Кому не следует это рассматривать
- Patients without a confirmed Meniere diagnosis by an otologist (other vestibular disorders need different treatment)
- Patients with severe sensorineural hearing loss in the only hearing ear (risk-benefit unfavorable)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
- О чём спросить врача
- Has my diagnosis of Meniere disease been confirmed by an otologist or neurotologist?
- Have I tried sodium restriction (under 1.5 g/day) and a thiazide diuretic for at least 6 months?
- What is the evidence base for leech therapy in Meniere — case reports only or controlled trials?
- Will the leech sessions worsen attacks during the treatment course?
- What hearing tests will be done before and after the course to track changes?
- If I do not improve, what intratympanic or surgical options remain available?
- Когда срочно обратиться за медицинской помощью
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden complete hearing loss in either ear
- New persistent vertigo lasting more than 24 hours that does not feel like a usual Meniere attack
Что это НЕ означает
- It does not mean leech therapy is FDA-cleared for Meniere disease — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace dietary sodium restriction, diuretic therapy, or vestibular rehab — those are the first-line interventions with the most evidence.
- It does not have any RCT evidence in Meniere; published reports are anecdotal.
- It does not stop the natural fluctuating course of Meniere — many patients have spontaneous remissions that can falsely appear to be treatment effects.
- It does not prevent the progressive hearing loss that occurs in most Meniere patients regardless of treatment.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- ent
- ICD-10
- H81.01, H81.02, H81.03, H81.09
- Safety tier
- medium
Evidence Summary
Definite Ménière's disease per AAO-HNS 2015 criteria (two or more spontaneous vertigo episodes ≥20 min, low-frequency SNHL, fluctuating aural symptoms) is conventionally managed with sodium restriction, betahistine, and intratympanic gentamicin or steroids for refractory cases. No controlled clinical trial or published case series of leech therapy for Ménière's vestibular attacks exists, and no clinical outcome data are available; any use is investigational and mechanistic only. A proposed mechanism involves endolymphatic hydrops modulation via local lymphatic decongestion, but this is speculative. Evidence grade is D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Cetinkaya EA et al. (2017), n=14
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active vestibular attack
- Recent intratympanic gentamicin (<6 weeks)
- Suspected vestibular schwannoma (rule out with MRI)
Related Conditions
Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.